Pain Sensitivity as a Functional Readout of Adrenal‑Driven Neuroimmune Aging

Hypothesis

Chronic pain sensitivity reflects adrenal‑driven neuroimmune aging: a high cortisol/DHEAS awakening ratio drives blood‑brain barrier leakage, microglial priming, and central sensitization, which in turn lowers pain thresholds and accelerates epigenetic aging independently of chronological age.

Mechanistic rationale

1. Adrenal glucocorticoid excess – With age, cortisol secretion remains relatively stable while DHEAS falls, raising the cortisol/DHEAS ratio. Elevated glucocorticoids increase expression of endothelial adhesion proteins and reduce tight‑junction integrity, permitting peripheral cytokines and catecholamines to enter the CNS [[https://pmc.ncbi.nlm.nih.gov/articles/PMC12357812/]].
2. Blood‑brain barrier (BBB) compromise – Leakage allows IL‑1β, TNF‑α, and norepinephrine to activate perivascular macrophages and microglia. Primed microglia release prostaglandin E2 and BDNF, enhancing neuronal excitability in spinal dorsal horn circuits [[https://pubmed.ncbi.nlm.nih.gov/25428852/]].
3. Central sensitization and pain thresholds – Heightened microglial signaling lowers the activation threshold of nociceptive neurons, manifesting as reduced heat and pressure pain tolerance in quantitative sensory testing [[https://pmc.ncbi.nlm.nih.gov/articles/PMC5621604/]].
4. Feedback to epigenetic aging – Persistent neuroinflammation sustains HPA‑axis activation, driving glucocorticoid‑responsive transcription factors (e.g., NF‑κB, GR) that alter DNA methylation patterns at aging‑related CpG sites. Simultaneously, loss of DHEA‑mediated glucocorticosteroid antagonism removes a protective neurosteroid brake on inflammatory signaling, accelerating epigenetic drift [[https://pmc.ncbi.nlm.nih.gov/articles/PMC6710702/]].
5. Vagal tone modulation – Elevated cortisol/DHEAS reduces heart‑rate variability, dampening cholinergic anti‑inflammatory pathways and further permitting microglial activation.

Testable predictions

• Prediction 1: In a cross‑sectional sample of adults aged 30‑80, the cortisol/DHEAS awakening ratio will predict heat pain threshold (HPT) and pressure pain threshold (PPT) after adjusting for age, sex, BMI, and baseline inflammation (CRP, IL‑6).
• Prediction 2: The same adrenal ratio will explain additional variance in epigenetic age (GrimAge) beyond chronological age and traditional risk factors, indicating that pain sensitivity captures functional neuroimmune aging not fully reflected by methylation clocks.
• Prediction 3: Acute pharmacological lowering of cortisol (e.g., metyrapone) or DHEA replacement in a randomized crossover trial will increase HPT/PPT and attenuate short‑term changes in methylation age‑associated CpGs after 4 weeks.

Experimental design (outline)

1. Cohort – Recruit 200 community‑dwelling adults, stratify by sex and decade of life.
2. Baseline measures – Morning cortisol and DHEAS (awakening +30 min), quantitative sensory testing (HPT via contact thermode, PPT via algometer), plasma cytokines, heart‑rate variability, and epigenetic age from saliva DNA (GrimAge).
3. Analysis – Hierarchical regression models testing the adrenal ratio as predictor of pain thresholds and epigenetic age; mediation analysis to assess whether pain thresholds mediate the ratio‑epigenetic age link.
4. Intervention sub‑study – 40 participants with highest cortisol/DHEAS ratio receive either metyrapone 750 mg nightly or DHEA 50 mg twice daily for 4 weeks in a double‑blind, crossover fashion; repeat pain testing and epigenetic sampling pre‑ and post‑intervention.
5. Falsifiability – If the adrenal ratio does not predict pain thresholds after covariate adjustment, or if manipulating cortisol/DHEAS fails to alter pain sensitivity or methylation markers, the hypothesis is refuted.

Potential impact

Linking a simple, low‑cost sensory test to adrenal neuroimmune dysregulation offers a functional biomarker that could complement molecular clocks, flag accelerated aging before disease onset, and guide personalized interventions targeting the HPA‑axis or neuroinflammatory pathways.